A review of body composition and pharmacokinetics in oncology

References

• Arrieta O, De La Torre-Vallejo M, Lopez-Macias D, et al. Nutritional status, body surface, and low lean body mass/body mass index are related to dose reduction and severe gastrointestinal toxicity induced by afatinib in patients with non-small cell lung cancer. Oncologist. 2015;20:967–974.
   PubMed Web of Science ®Google Scholar
• Prado CMM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629–635.
   PubMed Web of Science ®Google Scholar
• Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care. 2009;3:269–275.
   PubMedGoogle Scholar
• Smith KL, Tisdale MJ. Increased protein degradation and decreased protein synthesis in skeletal msucle during cancer cachexia. Br J Cancer. 1993;67:680–685.
   PubMed Web of Science ®Google Scholar
• Du Bois D, Du Bois E. A formula to esimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863–871.
   Google Scholar
• Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
   PubMed Web of Science ®Google Scholar
• Sawyer MB, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001;19:171–177.
   PubMed Web of Science ®Google Scholar
• Shuter B, Aslani A. Body surface area: Du Bois and Du Bois revisited. Eur J Appl Physiol. 2000;82.
   PubMed Web of Science ®Google Scholar
• Verbraecken J, Van De Heyning P, De Backer W, et al. Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism. 2006;55:515–524.
   PubMed Web of Science ®Google Scholar
• Beumer JH, Chu E, Salamone SJ. Body-surface area-based chemotherapy dosing: appropriate in the 21st century? J Clin Oncol. 2012;30:3896–3897.
   PubMed Web of Science ®Google Scholar
• Fang L, Xin W, Ding H, et al. Pharmacokinetically guided algorithm of 5-fluorouracil dosing, a reliable strategy of precision chemotherapy for solid tumors: a meta-analysis. Sci Rep. 2016;6:25913.
   PubMed Web of Science ®Google Scholar
• Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985). 2004;97:2333–2338.
   PubMed Web of Science ®Google Scholar
• Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31:1539–1547.
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39:412–423.
   PubMed Web of Science ®Google Scholar
• Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13:3264–3268.
   PubMed Web of Science ®Google Scholar
• Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15:2920–2926.
   PubMed Web of Science ®Google Scholar
• Sjoblom B, Gronberg BH, Benth JS, et al. Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer. 2015;90:85–91.
   PubMed Web of Science ®Google Scholar
• Sjoblom B, Benth JS, Gronberg BH, et al. Drug dose per kilogram lean body mass predicts hematologic toxicity from carboplatin-doublet chemotherapy in advanced non-small-cell lung cancer. Clin Lung Cancer. 2017;18:e129–e136.
   PubMed Web of Science ®Google Scholar
• Ali R, Baracos VE, Sawyer MB, et al. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med. 2016;5:607–616.
   PubMed Web of Science ®Google Scholar
• Cushen SJ, Power DG, Teo MY, et al. Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib. Am J Clin Oncol. 2017;40:47–52.
   PubMed Web of Science ®Google Scholar
• Antoun S, Birdsell L, Sawyer MB, et al. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010;28:1054–1060.
   PubMed Web of Science ®Google Scholar
• Huillard O, Mir O, Peyromaure M, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer. 2013;108:1034–1041.
   PubMed Web of Science ®Google Scholar
• Cousin S, Hollebecque A, Koscielny S, et al. Low skeletal muscle is associated with toxicity in patients included in phase I trials. Invest New Drugs. 2014;32:382–387.
   PubMed Web of Science ®Google Scholar
• Jung HW, Kim JW, Kim JY, et al. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer. 2015;23:687–694.
   PubMed Web of Science ®Google Scholar
• Tan BH, Brammer K, Randhawa N, et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol. 2015;41:333–338.
   PubMed Web of Science ®Google Scholar
• Anandavadivelan P, Brismar TB, Nilsson M, et al. Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients. Clin Nutr. 2016;35:724–730.
   PubMed Web of Science ®Google Scholar
• Daly LE, Power DG, O’Reilly A, et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer. 2017;116:310–317.
   PubMed Web of Science ®Google Scholar
• Chemama S, Bayar MA, Lanoy E, et al. Sarcopenia is associated with chemotherapy toxicity in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol. 2016;23:3891–3898.
   PubMed Web of Science ®Google Scholar
• Parsons HA, Tsimberidou AM, Pontikos M, et al. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr Cancer. 2012;64:206–217.
   PubMed Web of Science ®Google Scholar
• Srdic D, Plestina S, Sverko-Peternac A, et al. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value. Support Care Cancer. 2016;24:4495–4502.
   PubMed Web of Science ®Google Scholar
• Prado CM, Baracos VE, Xiao J, et al. The association between body composition and toxicities from the combination of doxil and trabectedin in patients with advanced relapsed ovarian cancer. Appl Physiol Nutr Metab. 2014;39:693–698.
   PubMed Web of Science ®Google Scholar
• Barret M, Antoun S, Dalban C, et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer. 2014;66:583–589.
   PubMed Web of Science ®Google Scholar
• Shachar SS, Deal AM, Weinberg M, et al. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res. 2017;23:658–665.
   PubMed Web of Science ®Google Scholar
• Prado CM, Lima IS, Baracos VE, et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol. 2011;67:93–101.
   PubMed Web of Science ®Google Scholar
• Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One. 2012;7:e37563.
   PubMed Web of Science ®Google Scholar
• Massicotte MH, Borget I, Broutin S, et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab. 2013;98:2401–2408.
   PubMed Web of Science ®Google Scholar
• Wong AL, Seng KY, Ong EM, et al. Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. Breast Cancer Res Treat. 2014;144:143–152.
   PubMed Web of Science ®Google Scholar
• Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997–1006.
   PubMed Web of Science ®Google Scholar